Skip to main content

Hemophilia A

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development
NCT01445197 | PHASE 3 | INTERVENTIONAL

This is a clinical study to investigate how well Biostate works in treatment of male patients below the age of 12 years who have a clotting factor deficiency that is aggravated by the development of antibodies. The antibodies are directed against the clotting factor that is given for replacement therapy and usually make therapy unsuccessful. The treatment used in this study is called immune tolerance therapy.

Trial Information
7 Sites
1 Participants
Recruiting
28 Days to 11 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Vienna,Austria
Study Site
Frankfurt,Germany
Study Site
Hamburg,Germany
Study Site
Athens,Greece
Study Site
Thessaloniki,Greece
Study Site
Milano,Italy
Study Site
Barnaul,Russian Federation

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov